Search results
Showing 1 to 15 of 399 results for stroke
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.
View quality statements for QS2Show all sections
Sections for QS2
- Quality statements
- Quality statement 1: Prompt admission to specialist acute stroke units
- Quality statement 2: Intensity of stroke rehabilitation
- Quality statement 3: Access to a clinical psychologist
- Quality statement 4: Early supported discharge
- Quality statement 5: Return to work
- Quality statement 6: Regular review of rehabilitation goals
- Quality statement 7: Regular review of health and social care needs
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
All NICE products on stroke and transient ischaemic attack. Includes any guidance, advice and quality standards.
Evidence-based recommendations on tenecteplase (Metalyse) for treating acute ischaemic stroke in adults.
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.
Awaiting development Reference number: GID-TA10426 Expected publication date: TBC
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke
Stroke and ischaemic attack: 90% of time on a stroke unit (IND35)
This indicator covers the proportion of patients who have had an acute stroke who spend 90% or more of their stay on a stroke unit. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG52
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke
Stroke and ischaemic attack: 4-hour admission to a stroke unit (IND34)
This indicator covers the proportion of people who have had or are having a stroke who are admitted to an acute stroke unit within 4 hours of arrival to hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG51
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.